In the news

Regeneus Ltd receives $2.7M for regenerative medicine product pipeline

Regeneus will progress its regenerative medicine product pipeline with its recent $2.73 million funding from the Australian government, bestowed as part of a research and development tax refund.

CEO John Martin will deliver a company spotllight presentation at Australia Biotech Invest. 

Read more in Proactive Investors Hong Kong.  

FDA approves IND for Novogen's Cantrixil study

Novogen (ASX:NRT) has announced it has received confirmation from the US FDA that the Investigational New Drug (IND) application for Cantrixil (TRX-E-002-1) has been successfully opened, and the phase I study of Cantrixil in patients with ovarian cancer can proceed as planned.

CEO Dr James Garner will deliver Novogen's company spotlight presentation at Australia Biotech Invest. 

Read more in Biotech Dispatch

Race Oncology secures NPP marketer

Race Oncology has elected CarthaGenetics to handle the launch of its Named Patient Program (NPP) in Europe, and to distribute and sell Bisantrene under the program.

Race Oncology's company spotlight presentation will be delivered by CEO Peter Molloy at Australia Biotech Invest.

Read more from news.com.au

Adherium expands international presence and announces new appointments

Adherium Limited (ASX:ADR) has announced Mr Thomas Lynch as its new chairman and Dr Doug Wilson as executive medical director. Recently established business hubs in the US and the UK are accelerating Adherium's access to business. The Adherium technology platform is developing with new devices incorporating more sensors to broaden the application beyond drug detection to inhaler technique and other data. 

Garth Sutherland, Group CEO, Adherium will deliver a company spotlight presentation at Australia Biotech Invest. 

Read more in Biotech Dispatch

AdAlta receives Australian government grant to advance understanding of potential new lung fibrosis therapy

Biotechnology company AdAlta Limited (ASX: 1AD), specialising in the discovery and development of protein-based therapeutics has received a AU$50,000 Innovation Connections Grant From the Australian Federal Government to support research with The Alfred Hospital and La Trobe University in Melbourne.

“This collaboration is important as we move towards first human clinical studies with our lead i-body drug candidate for the treatment of idiopathic pulmonary fibrosis," said CEO Sam Cobb.

Mr Cobb will deliver AdAlta's company spotlight presentation at Australia Biotech InvestRead more in Biospace.

Phosphagenics begins feed efficiency study in broilers

Phosphagenics Ltd (ASX:POH) has initiated the next phase in its animal health and nutrition "Livestock Feed Efficiency Program" with the commencement of a poultry study in broilers. The study will enable Phosphagenics to assess the utility of Targeted Penetration Matrix (TPM) to improve feed efficiency across multiple species by the end of the year.

Dr Ross Murdoch, CEO & Managing Director, Phosphagenics will deliver a spotlight presentation at Australia Biotech Invest.

Read more in Proactive Investors.

Regeneus FY16 Results

Clinical-stage regenerative medicine company Regenus Ltd (ASX:RGS) report their 2016 financial results and business update. 

"Last financial year we achieved a number of important R&D, clinical, and commercial milestones that set the platform for unlocking significant shareholder value in the business over the next 12 months," said CEO John Martin. 

Mr Martin will deliver Regeneus' company spotlight presentation at Australia Biotech Invest

Read more in ABN Newswire

Adelaide biotech company Reproductive Health Science to launch latest product to global market

Adelaide-based biotechnology company Reproductive Health Science (ASX:RHS) is launching its second product, DOPlify, onto the global market. 

“With significant performance advantages over other products, DOPlify provides a platform for RHS to expand our target market into such areas as understanding cancer, plant and animal science and forensics as well as broader clinical and research applications,” said Managing Director Dr Michelle Fraser. 

Dr Michelle Fraser will deliver Reproductive Health Science's spotlight presentation at Australia Biotech Invest 2016. 

Read more in Biotech Dispatch